Acquisition extends ICON's presence in the market for government
sponsored research and enhances capabilities in Vaccines and Infectious
Disease
DUBLIN--(BUSINESS WIRE)--
ICON
plc, (NASDAQ:ICLR) a global provider of drug development
solutions and services to the pharmaceutical, biotechnology and medical
device industries, today announced that it has completed the previously
announced acquisition of Clinical Research Management, Inc. (ClinicalRM).
ClinicalRM provides full service and functional research solutions to a
broad range of U.S. government agencies. Their extensive expertise
extends across basic and applied research, infectious diseases, vaccine
development and testing and response to bio-threats. In addition, they
have worked in collaboration with government and commercial customers to
respond to the threat of global viral epidemics.
Commenting on the acquisition, ICON's Chief Executive Officer, Ciaran
Murray said: "ClinicalRM has a strong track record of partnering
successfully with government agencies and NGOs. They will provide a
platform for ICON to further penetrate this significant market segment
as we continue to grow and diversify our customer base. ClinicalRM's
work in the area of global vaccine development will further enhance our
capabilities in this important area to the benefit of customers and
patients globally."
About ClinicalRM
ClinicalRM is a full-service Contract Research Organization specializing
in preclinical through Phase IV support of clinical research and
clinical trial services for biologics, drugs and devices. The
organization helps customers get their products to market faster with a
wide array of research, regulatory and sponsor services within the U.S.
and around the globe. From international partnerships and affiliations
to government relations and local alliances, ClinicalRM delivers a
synergy in the global market with projects spanning the government,
academic and commercial marketplaces. ClinicalRM has a distinct ability
to provide boots-on-the-ground and rapid response efforts to global
health crises. More information is at http://www.clinicalrm.com/
About ICON plc
ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. ICON
specialises in the strategic development, management and analysis of
programs that support clinical development - from compound selection to
Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON
currently operates from 89 locations in 37 countries and has
approximately 12,300 employees.
Further information is available at www.iconplc.com
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at http://www.sec.gov.
ICON/ICLR-F
View source version on businesswire.com: http://www.businesswire.com/news/home/20160919005486/en/
ICON Media Contact
Niamh Murphy
ICON
+35312912180
niamh.murphy@iconplc.com
Source: ICON plc
News Provided by Acquire Media
